Lv4
572 积分 2023-07-24 加入
KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants
4天前
已完结
Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation
4天前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
5天前
已完结
Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability
7天前
已完结
Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses
7天前
已完结
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
8天前
已完结
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy
8天前
已完结
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
9天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
9天前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
9天前
已完结